Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1076
CALL
Jazz Pharmaceuticals
JAZZ
$16.1B
| $27M | 0.01% |
158,700
+93,200
| +142% | +$14.3M |
|
1077
Xenon Pharmaceuticals
XENE
$6.11B
| $26.9M | 0.01% |
600,964
+489,664
| +440% | +$20.6M |
|
1078
Fidelity National Financial
FNF
$12.8B
| $26.9M | 0.01% |
493,226
+54,064
| +12% | +$3.08M |
|
1079
Hecla Mining
HL
$11.9B
| $26.9M | 0.01% |
1,400,466
+521,597
| +59% | +$7.97M |
|
1080
HEICO Corp Class A
HEI.A
$37B
| $26.7M | 0.01% |
105,926
+8,837
| +9% | +$2.18M |
|
1081
Planet Labs
PL
$8.45B
| $26.7M | 0.01% |
1,354,421
-2,373,322
| -64% | -$34M |
|
1082
Huazhu Hotels Group
HTHT
$12.8B
| $26.5M | 0.01% |
564,284
+313,703
| +125% | +$13.5M |
|
1083
PUT
Pentair
PNR
$10.7B
| $26.5M | 0.01% |
+254,800
| New | +$27.2M |
|
1084
Arcus Biosciences
RCUS
$3.66B
| $26.5M | 0.01% |
1,112,258
+935,178
| +528% | +$19.1M |
|
1085
Match Group
MTCH
$8.45B
| $26.5M | 0.01% |
820,640
-649,066
| -44% | -$21.3M |
|
1086
PUT
Dollar Tree
DLTR
$24.6B
| $26.4M | 0.01% |
215,000
+120,000
| +126% | +$12.9M |
|
1087
Encompass Health
EHC
$12.4B
| $26.4M | 0.01% |
248,885
+108,669
| +78% | +$12.6M |
|
|
CSGS
1088
DELISTED
CSG Systems International
CSGS
| $26.3M | 0.01% |
343,325
-134,615
| -28% | -$9.93M |
|
1089
Freshpet
FRPT
$3.45B
| $26.1M | 0.01% |
429,121
+15,548
| +4% | +$882K |
|
1090
Illumina
ILMN
$29.1B
| $26.1M | 0.01% |
199,302
-72,673
| -27% | -$8.53M |
|
1091
BlackLine
BL
$1.63B
| $26.1M | 0.01% |
472,010
+19,153
| +4% | +$1.05M |
|
1092
Repligen
RGEN
$9.3B
| $26.1M | 0.01% |
159,152
-97,690
| -38% | -$15.3M |
|
1093
Molson Coors Class B
TAP
$7.83B
| $26M | 0.01% |
557,495
-346,485
| -38% | -$16M |
|
1094
Rubrik
RBRK
$20B
| $26M | 0.01% |
339,806
-6,456
| -2% | -$495K |
|
1095
EnerSys
ENS
$6.79B
| $26M | 0.01% |
176,966
+39,179
| +28% | +$5.23M |
|
1096
Healthpeak Properties
DOC
$14.1B
| $25.9M | 0.01% |
1,610,702
+115,177
| +8% | +$2.03M |
|
1097
BWX Technologies
BWXT
$15.5B
| $25.8M | 0.01% |
149,500
-20,311
| -12% | -$3.81M |
|
1098
CALL
Sunrun
RUN
$2.42B
| $25.8M | 0.01% |
1,403,400
-1,255,500
| -47% | -$24.1M |
|
1099
PUT
Baxter International
BAX
$14.3B
| $25.8M | 0.01% |
+1,350,000
| New | +$27M |
|
1100
UiPath
PATH
$8.14B
| $25.8M | 0.01% |
1,572,586
+548,671
| +54% | +$8.54M |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.